Diet pill Acomplia is a miraculous multifunctional pill that helps you short out obesity as well as smoking. This wonder pill selectively blocks some receptors in the Endocannabinoid system, thus creating a better balance which in turn suppresses appetite and the longing to overeat. Basic research has demonstrated that the endocannabinoid system plays an integral role in the regulation of food intake, metabolism and storage.
Acomplia 20 mg tablet is taken once daily in the morning before breakfast. If you miss a daily dose take another dosage the following day, if you are late taking your dosage you can take it before your next meal.
Acomplia... What is it?
• Acomplia (rimonabant) is the first in a new class of therapeutic agents called Cannabinoid-1 Receptor Blockers (CB1).
• Acomplia is used in the treatment of obesity and related conditions.
Acomplia common features
Acomplia acts by selectively blocking CB1 receptors found in the brain and in peripheral organs important in glucose and lipid (or fat) metabolism, including adipose tissue, the liver, gastrointestinal tract and muscle. Acomplia switches off the same brain circuits that make people hungry when they smoke cannabis. CB1 receptor blockade with Acomplia acts to decrease the overactivity of the endocannabinoid system (EC system). The EC system is a recently characterised physiological system that includes receptors such as the CB1 receptor and it has been shown to play an important role in regulating body weight and in controlling energy balance, as well as glucose and lipid (or fat) metabolism.
Acomplia is used complementary to diet and exercise to treat obese or overweight patients who suffer from Type 2 diabetes and abnormal levels of fat in the blood. Sanofi argues that Acomplia can also prevent the risk of cardiovascular disease. Patients with large waist circumference (102 cm in men and 88 cm in women) will mostly benefit from taking the drug.
In clinical studies, Acomplia has been shown to improve a wide array of cardiometabolic risk factors as well as promoting sustained weight loss.
Approximately half of the observed improvement in HDL-cholesterol, triglycerides and HbA1C (an indicator of blood sugar control) in patients who received Acomplia 20mg was beyond that expected from weight loss alone.
Side effects in the trial on Acomplia in obesity were vomiting and nausea, forcing about 19 percent of patients to leave the trial versus 13 percent of those who took placebo.